Ningbo Menovo Pharmaceutical (603538.SH) subsidiary obtains registration certificate for Nifedipine tablets.
Meinuo Hua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meinuo Hua Tiankang Pharmaceutical Co., Ltd. (hereinafter referred to as "Meinuo Hua Tiankang"), recently received the Drug Registration Certificate for Febuxostat Tablets issued by the National Medical Products Administration. The indication of the drug is for the long-term treatment of hyperuricemia in patients with gout.
Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary Ningbo Menovo Pharmaceutical Tiankang Pharmaceutical Co., Ltd. ("Ningbo Menovo Pharmaceutical Tiankang") recently received the approved and issued "Drug Registration Certificate" from the National Medical Products Administration. The indication for the drug is for the long-term treatment of hyperuricemia in patients with gout.
Related Articles
IGG (00799) spent 756,600 Hong Kong dollars to repurchase 200,000 shares on December 10th.
TIME INTERCON (01729) issued 21.7334 million shares of consideration shares based on general authorization.
POWERLONG (01238): The application for liquidation of the subsidiary has been withdrawn.
IGG (00799) spent 756,600 Hong Kong dollars to repurchase 200,000 shares on December 10th.
TIME INTERCON (01729) issued 21.7334 million shares of consideration shares based on general authorization.
POWERLONG (01238): The application for liquidation of the subsidiary has been withdrawn.
RECOMMEND
McDonald’s to Evaluate Franchisee Pricing for Customer Value Under Revised Standards
10/12/2025
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
